Aileron Therapeutics (ALRN) Competitors Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends ALRN vs. ZNTL, HURA, IKT, CYBN, CGEN, CRDF, ACRS, SLN, SCPH, and ALECShould you be buying Aileron Therapeutics stock or one of its competitors? The main competitors of Aileron Therapeutics include Zentalis Pharmaceuticals (ZNTL), TuHURA Biosciences (HURA), Inhibikase Therapeutics (IKT), Cybin (CYBN), Compugen (CGEN), Cardiff Oncology (CRDF), Aclaris Therapeutics (ACRS), Silence Therapeutics (SLN), scPharmaceuticals (SCPH), and Alector (ALEC). These companies are all part of the "pharmaceutical products" industry. Aileron Therapeutics vs. Zentalis Pharmaceuticals TuHURA Biosciences Inhibikase Therapeutics Cybin Compugen Cardiff Oncology Aclaris Therapeutics Silence Therapeutics scPharmaceuticals Alector Zentalis Pharmaceuticals (NASDAQ:ZNTL) and Aileron Therapeutics (NASDAQ:ALRN) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, risk, profitability, earnings, dividends, analyst recommendations, community ranking, valuation and institutional ownership. Do insiders & institutionals believe in ZNTL or ALRN? 90.9% of Aileron Therapeutics shares are owned by institutional investors. 3.6% of Zentalis Pharmaceuticals shares are owned by insiders. Comparatively, 5.1% of Aileron Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has better valuation & earnings, ZNTL or ALRN? Zentalis Pharmaceuticals is trading at a lower price-to-earnings ratio than Aileron Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioZentalis PharmaceuticalsN/AN/A-$292.19M-$2.49-0.90Aileron TherapeuticsN/AN/A-$15.73M-$3.12N/A Does the MarketBeat Community believe in ZNTL or ALRN? Aileron Therapeutics received 154 more outperform votes than Zentalis Pharmaceuticals when rated by MarketBeat users. Likewise, 66.98% of users gave Aileron Therapeutics an outperform vote while only 63.44% of users gave Zentalis Pharmaceuticals an outperform vote. CompanyUnderperformOutperformZentalis PharmaceuticalsOutperform Votes5963.44% Underperform Votes3436.56% Aileron TherapeuticsOutperform Votes21366.98% Underperform Votes10533.02% Does the media refer more to ZNTL or ALRN? In the previous week, Zentalis Pharmaceuticals had 3 more articles in the media than Aileron Therapeutics. MarketBeat recorded 4 mentions for Zentalis Pharmaceuticals and 1 mentions for Aileron Therapeutics. Zentalis Pharmaceuticals' average media sentiment score of 1.11 beat Aileron Therapeutics' score of -0.33 indicating that Zentalis Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zentalis Pharmaceuticals 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aileron Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more risk and volatility, ZNTL or ALRN? Zentalis Pharmaceuticals has a beta of 1.86, meaning that its stock price is 86% more volatile than the S&P 500. Comparatively, Aileron Therapeutics has a beta of 2.24, meaning that its stock price is 124% more volatile than the S&P 500. Is ZNTL or ALRN more profitable? Zentalis Pharmaceuticals' return on equity of -43.91% beat Aileron Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Zentalis PharmaceuticalsN/A -43.91% -34.96% Aileron Therapeutics N/A -74.08%-27.93% Do analysts recommend ZNTL or ALRN? Zentalis Pharmaceuticals currently has a consensus price target of $10.00, suggesting a potential upside of 346.43%. Aileron Therapeutics has a consensus price target of $19.00, suggesting a potential upside of 0.00%. Given Zentalis Pharmaceuticals' higher possible upside, analysts plainly believe Zentalis Pharmaceuticals is more favorable than Aileron Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zentalis Pharmaceuticals 0 Sell rating(s) 5 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.44Aileron Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50 SummaryAileron Therapeutics beats Zentalis Pharmaceuticals on 9 of the 15 factors compared between the two stocks. Get Aileron Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ALRN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALRN vs. The Competition Export to ExcelMetricAileron TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$45.72M$6.22B$5.21B$9.14BDividend YieldN/A2.94%5.13%4.02%P/E RatioN/A9.9189.4217.36Price / SalesN/A309.211,240.0477.11Price / CashN/A61.4443.7535.97Price / BookN/A6.055.314.79Net Income-$15.73M$154.90M$122.54M$225.00M Aileron Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALRNAileron Therapeutics3.1038 of 5 starsN/A$19.00+∞N/A$45.72MN/A0.009News CoverageZNTLZentalis Pharmaceuticals2.9394 of 5 stars$2.56-6.9%$10.00+290.6%-82.6%$182.44M$40.56M-1.03160Positive NewsHURATuHURA BiosciencesN/A$4.31-11.1%$13.00+201.6%N/A$182.25MN/A0.00N/APositive NewsIKTInhibikase Therapeutics1.6593 of 5 stars$2.66-9.8%$6.50+144.4%+58.2%$178.73M$260,000.00-1.006Positive NewsGap DownCYBNCybin2.9361 of 5 stars$8.90+0.1%$138.00+1,450.6%N/A$177.93MN/A-1.3450Positive NewsCGENCompugen2.2714 of 5 stars$1.99+21.3%$4.00+101.0%+16.0%$177.58M$59.85M99.5070Positive NewsHigh Trading VolumeCRDFCardiff Oncology2.1519 of 5 stars$3.47-3.9%$10.33+197.8%+128.5%$177.44M$688,000.00-3.6920Positive NewsACRSAclaris Therapeutics4.0912 of 5 stars$2.48+0.4%$11.00+343.5%+125.4%$177.15M$27.08M-4.7786Short Interest ↑Positive NewsHigh Trading VolumeSLNSilence Therapeutics2.1074 of 5 stars$5.90-1.5%$57.20+869.5%-72.2%$176.58M$16.25M-3.76100SCPHscPharmaceuticals3.3354 of 5 stars$3.51+3.2%$15.00+327.4%-38.6%$175.64M$30.28M-1.8530ALECAlector4.5046 of 5 stars$1.79-0.6%$3.75+109.5%-70.9%$175.30M$61.51M-1.05270Short Interest ↓ Related Companies and Tools Related Companies Zentalis Pharmaceuticals Alternatives TuHURA Biosciences Alternatives Inhibikase Therapeutics Alternatives Cybin Alternatives Compugen Alternatives Cardiff Oncology Alternatives Aclaris Therapeutics Alternatives Silence Therapeutics Alternatives scPharmaceuticals Alternatives Alector Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ALRN) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | SponsoredA deadly mistake in my prediction…I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aileron Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aileron Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ALRN Stock Alerts